Category: Research

A growing body of research is pointing to C-peptide, a byproduct released when the body produces its own insulin, as a valuable and increasingly accepted measurement in type 1 diabetes (T1D) clinical trials. Advocacy organizations like Breakthrough T1D are highlighting this shift as an encouraging step forward for the field, one that could help bring new treatments to patients more efficiently.

C-peptide levels serve as a reliable indicator of how much insulin a person’s own pancreas is still producing. For people in the early stages of T1D, or those enrolled in trials testing therapies designed to protect or restore insulin-producing beta cells, tracking C-peptide offers researchers a clearer, more direct way to see whether a treatment is working. This matters because preserving even a modest amount of natural insulin production has been associated with better blood sugar stability and fewer complications over time.

Using C-peptide as a standardized trial endpoint could also streamline the regulatory review process. When trial sponsors and regulators agree on a consistent, well-validated measurement, it becomes easier to compare results across different studies and therapies. This kind of consistency is often a key ingredient in accelerating the pace at which promising treatments move from the lab to the clinic.

For the T1D community, this development reflects years of collaborative work between researchers, clinicians, and advocacy groups pushing for trial designs that better reflect meaningful biological outcomes. As more trials adopt C-peptide tracking, it may become easier to identify which emerging therapies, including various peptide-based and immune-modulating approaches, are genuinely preserving beta cell function. That, in turn, could help channel resources toward the most promising candidates and potentially shorten the path to new options for people living with type 1 diabetes.

While there is still work to be done in fully standardizing how C-peptide data is collected and interpreted across different trial settings, the increasing recognition of its value is viewed as a positive sign of scientific progress. This is for informational purposes only and not medical advice.

Curated by True North Labs. More at truenorthlabs.co. Informational only – not medical advice.

Source: C-Peptide as an Endpoint in Clinical Trials: Its Time Has Come – Breakthrough T1D

Researchers are exploring a refined statistical approach to measuring C-peptide levels over time that could make clinical trials for type 1 diabetes (T1D) more efficient and informative. C-peptide, a byproduct of insulin production, serves as a key biomarker for how much insulin-producing capacity a person with T1D still has. According to work highlighted by biostatistician Samuel Shangwu Wu, PhD, and reported by AJMC, using a longitudinal endpoint that tracks C-peptide changes over the full course of a trial—rather than relying on a single snapshot measurement—may better capture the true impact of emerging therapies.

This shift in trial design matters because many promising T1D treatments, including various peptide-based and immunotherapy approaches, aim to slow or preserve the body’s remaining insulin production, especially in the early stages after diagnosis. Traditional endpoints that measure C-peptide at just one or two time points can miss meaningful trends or fluctuations, potentially underselling a therapy’s real benefit or requiring larger, more expensive trials to detect an effect. A longitudinal approach, by contrast, uses repeated measurements to build a fuller picture of how a treatment influences insulin-producing beta cell function throughout the study period.

For patients and families affected by type 1 diabetes, this kind of methodological advancement is good news even though it isn’t a treatment itself. Better trial design means researchers can potentially detect real treatment effects with fewer participants and shorter timelines, which historically translates into faster answers about whether a therapy works. It could also help scientists more accurately compare the effectiveness of different interventions, from novel peptides to immune-modulating drugs, giving the field clearer guidance on which approaches deserve further investment and development.

This kind of statistical innovation reflects a broader trend in T1D research: as more therapies enter the pipeline aimed at preserving beta cell function, especially in newly diagnosed patients, having precise and sensitive tools to measure success becomes increasingly important. Improved endpoints like this one could help accelerate the path from promising early trial results to therapies that meaningfully extend the period during which a person’s body still produces some of its own insulin.

While this development is centered on trial methodology rather than a new drug or therapy, it represents the kind of behind-the-scenes progress that often paves the way for faster, more reliable breakthroughs down the road. This article is for informational purposes only and is not medical advice.

Curated by True North Labs. More at truenorthlabs.co. Informational only – not medical advice.

Source: Longitudinal C-Peptide End Point Could Strengthen T1D Trial Design: Samuel Shangwu Wu, PhD – AJMC

A peptide compound first identified by researchers in Croatia during the 1990s is now experiencing a surge of interest in the United States, bringing renewed attention to the scientists whose early work laid the groundwork for today’s growing peptide research landscape. The story is a reminder that scientific breakthroughs often take unexpected paths before reaching wider recognition.

The original research, conducted decades ago, explored the properties of a peptide that has since become a subject of interest among researchers and wellness communities alike. As peptide science has expanded rapidly in recent years, driven by advances in synthesis, delivery methods, and a broader understanding of how peptides interact with biological systems, older discoveries like this one are being revisited with fresh eyes and modern tools.

This kind of cross-generational, cross-border scientific journey highlights something important about the peptide field: foundational research doesn’t lose its value with time. Instead, it often becomes the seed for new investigations, product development, and clinical curiosity years or even decades later. The Croatian team’s early work is now part of a larger conversation happening among scientists, biotech companies, and consumers in the US who are increasingly curious about peptide-based approaches to health and performance.

For the original researchers, seeing their work move into the spotlight after so many years is a meaningful validation of their early scientific instincts. It also underscores the collaborative, global nature of peptide science, where discoveries made in one country can ripple outward and influence research and innovation elsewhere. As more attention flows toward this compound, it may encourage renewed academic interest, further studies, and a deeper understanding of its properties and potential applications.

Stories like this help illustrate the long arc of scientific progress, showing how patience, curiosity, and rigorous early research can eventually pay dividends far beyond their original context. As the peptide field continues to grow, we may see more instances of overlooked or under-recognized discoveries finding new audiences and applications.

This article is for informational purposes only and is not intended as medical advice.

Curated by True North Labs. More at truenorthlabs.co. Informational only – not medical advice.

Source: Croatian researchers thrust into limelight as their 1990s’ peptide discovery goes mainstream in the US – Chemistry World

Retatrutide has become one of the most talked-about investigational peptides in metabolic health research. Unlike single-target therapies, retatrutide is designed to activate three different receptors—GLP-1, GIP, and glucagon—giving it a unique triple-action mechanism that researchers believe may offer more comprehensive metabolic benefits than existing options.

Early-phase clinical trials have generated considerable interest because of the magnitude of weight loss observed among participants, along with encouraging signals related to blood sugar regulation and other markers of metabolic health. Because retatrutide engages multiple hormonal pathways involved in appetite regulation, energy expenditure, and glucose metabolism, scientists are optimistic that it could eventually complement or expand the toolkit available for supporting healthy weight management.

Beyond weight-related outcomes, researchers are also examining how the combined receptor activity of retatrutide might influence other aspects of metabolic function, including lipid profiles and liver fat content. While these areas of investigation are still developing, the breadth of potential benefits being studied reflects the growing scientific enthusiasm surrounding multi-receptor agonist peptides as a promising direction for future therapies.

It’s important to note that retatrutide remains an investigational compound, meaning it has not yet completed the full clinical trial and regulatory approval process required for widespread medical use. Continued research, including larger and longer-duration studies, will help clarify its long-term safety profile and confirm the benefits observed so far. The scientific community will be watching closely as more data becomes available in the coming years.

The ongoing research into retatrutide highlights how innovation in peptide science continues to open new possibilities for metabolic health. As with any emerging therapy, patience and rigorous science are essential before it can become part of standard care.

This article is for informational purposes only and is not intended as medical advice.

Curated by True North Labs. More at truenorthlabs.co. Informational only – not medical advice.

Source: Potential Retatrutide Benefits You Should Know About – GoodRx

The peptide therapeutics field continues to attract significant investment, with San Diego-based Aizen recently announcing a partnership structured to deliver up to $100 million per target. Deals of this scale reflect growing confidence from the biotech and pharmaceutical industries in the potential of peptide-based drug candidates to address unmet medical needs.

While specific details about the therapeutic targets remain closely tied to ongoing research and development plans, the size and structure of this agreement highlight a broader trend: peptides are increasingly viewed as a promising modality for developing precise, targeted treatments. San Diego has long been a hub for biotech innovation, and deals like this reinforce the region’s role in advancing peptide science from the lab toward potential clinical applications.

Substantial per-target funding arrangements like this one are particularly meaningful because they provide the resources needed to move peptide candidates through the lengthy and expensive process of discovery, optimization, and preclinical testing. This kind of capital infusion can accelerate timelines, allowing promising peptide compounds to reach the stage of clinical trials more efficiently than might otherwise be possible with more limited funding.

For the broader peptide research community, news of major investment deals serves as an encouraging signal. It suggests that industry leaders continue to see strong scientific and commercial potential in peptide therapeutics across a range of possible applications. As more capital flows into this space, it may help support continued innovation, new discoveries, and eventually a wider array of treatment options for patients.

As with any early-stage biotech partnership, it will take time before we know which specific therapeutic targets emerge from this collaboration or what the eventual clinical outcomes might be. True North Labs will continue to monitor developments in the peptide research space and share updates as they unfold. This article is for informational purposes only and is not medical advice.

Curated by True North Labs. More at truenorthlabs.co. Informational only – not medical advice.

Source: Aizen Raises Up to $100M Per Target in San Diego Biotech Peptide Deal – The Clinical Trial Vanguard

Researchers publishing in Experimental & Molecular Medicine have reported that GV1001, a peptide derived from human telomerase reverse transcriptase, was able to rescue signs of neurodegeneration in a mouse model of Alzheimer’s disease. The study adds to a growing body of research exploring how peptide-based approaches might help address the complex biological changes seen in neurodegenerative conditions.

GV1001 has previously been studied for its potential roles in cellular protection and immune modulation, but this new work focused specifically on its effects within the brain. In the mouse model used to mimic aspects of Alzheimer’s disease, treatment with the peptide was associated with improvements in markers of neurodegeneration, suggesting that it may help support neuronal health under disease-related stress.

While the exact mechanisms are still being investigated, the researchers point to GV1001’s known biological activities—including potential effects on cellular stress responses—as possible explanations for the observed benefits. Alzheimer’s disease remains one of the most challenging conditions to treat, largely because it involves multiple overlapping processes, including protein aggregation, inflammation, and progressive neuronal loss. Any research pathway that shows measurable improvement in animal models is considered a meaningful step forward by the scientific community.

It’s important to note that this research was conducted in a mouse model, and translating findings from animal studies to human treatments is a long and rigorous process involving further preclinical work and, eventually, human clinical trials. Still, this study contributes valuable insight into how telomerase-derived peptides might be leveraged in future neuroscience research, and it opens the door to further investigation into GV1001’s potential role in supporting brain health.

As with all emerging peptide research, these findings are early-stage and highlight promising directions rather than ready-to-use treatments. This article is for informational purposes only and is not medical advice.

Curated by True North Labs. More at truenorthlabs.co. Informational only – not medical advice.

Source: A human telomerase reverse transcriptase-derived peptide GV1001 rescues neurodegeneration in a mouse model of Alzheimer disease | Experimental & Molecular Medicine – nature.com